KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration…
Read More
VESTECK Scientific Advisory Board members address significant global unmet need See more here
Read More
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder See more here
Read More
Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults Cefepime-taniborbactam has also demonstrated in vitro activity against CDC Urgent and Serious Threat Pathogens carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa and Extended Spectrum Beta-lactamase-producing Enterobacterales In the…
Read More
Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US Growing Global Incidence of Carbapenem-Resistant Enterobacterales Metallo-beta-lactamases were the most frequently identified carbapenem resistance mechanism among Enterobacterales isolates in IHMA global surveillance See more here
Read More
Immunome Reports Second Quarter 2023 Financial Results See more here
Read More
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results See more here
Read More
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic…
Read More
Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita See more here
Read More
KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement…
Read More